NITI Aayog holds meet on API industry with Cipla, Biocon, Zydus, Sun Pharma & more

New Delhi: A meeting to discuss the Active Pharmaceutical Ingredients (API) industry was organized yesterday in NITI Aayog under the chairmanship of NITI CEO Amitabh Kant. The Department of Pharmaceuticals made a detailed presentation on the history and status of the API industry and the challenges faced by it and the various options available to make India a powerhouse in Key Starting Materials, Intermediates, and Active Pharmaceuticals Ingredients.

DoP shared its vision and recent efforts in promoting bulk drug parks in the country. Issues related to environmental clearances were discussed in detail and the industry was promised fast approvals.

Principal Secretary (Industry), Government of Telangana, explained various incentives offered by the Government of Telangana and invited the industry to set up manufacturing units in Hyderabad Pharma City.

Leaders of the pharma industry shared their perspective on the situation and suggested various measures to be taken by the government.

Amitabh Kant exhorted the industry to become internationally competitive and go for a global scale of operations. He assured that the Union Government will take all necessary steps to support the industry in its endeavours.

Secretaries from the Department of Pharmaceuticals (DoP); Ministry of Environment, Forest and Climate Change (MoEFCC); Department of Health Research; and senior officers from the Department of Expenditure, Department of Chemicals and Petrochemicals, NITI Aayog, Department of Pharmaceuticals, and CDSCO attended the meeting. Representatives of the pharma industry, including Kiran Majumdar Shah (Biocon), Pankaj Patel (Zydus), Satish Reddy (Dr Reddy Laboratories), and senior officers of Sun Pharma, Aurobindo, Jubilant Life Sciences, Cipla, Mylan, Alembic, and Themis also attended the meeting. Presidents Bulk Drug Manufacturers Association, Indian Drug Manufacturers Association and Indian Pharmaceutical Alliance were also present.

Follow Indus Dictum on Facebook, Twitter, and LinkedIn for the latest updates.

Subscribe to Indus Dictum to receive a briefing about the latest news & feature articles. No spam, we promise.

Success! You're on the list.

The ID Staff

Daily stories by the Indus Dictum Staff

Have some feedback for the author? Click here to comment.